Symtuza
Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis
April 12, 2019Medical Communications HIV, Janssen, Symtuza, pharma
Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …
NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza
October 1, 2018Sales and Marketing HIV, Janssen, NHS, Symtuza, pharma
Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its …
Janssen’s Symtuza scores approval with the FDA in HIV-1
July 18, 2018Sales and Marketing HIV, Janssen, Symtuza, pharma
Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …
Latest content
Pharma sees climate disruption as growing supply-chain risk
September 11, 2026
Manchester NHS-MHRA partnership to test new technologies in real-world care
September 10, 2026
